Abstract
Driven by the development of new techniques, such as DNA microarrays, mass spectroscopy, tissue microarrays or protein chips, a large number of biomarkers have been identified in the past few years with the aim to classify cancer subtypes or to predict disease progression or therapeutic response. However, few of the described markers have been developed into clinically validated diagnostic tools. This review provides an overview of recent cancer biomarker developments and the difficulties of moving biomarkers from basic research into the clinic.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
